Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is a promising biotechnology company with a strong focus on developing transformative therapeutics for retinal diseases using its proprietary ABC platform. The company has a diversified pipeline with three late-stage clinical programs, including tarcocimab and KSI-501, which are being explored for retinal vascular diseases with topline data readouts expected in 2026 and 2027. With its innovative approach and high-potential products, Kodiak Sciences has a positive outlook and an appealing price target of $61, supported by its strong clinical data, successful trial results, and expected revenue growth.

Bears say

Kodiak Sciences is a biopharmaceutical company that has developed a new technology platform for retinal medicines, but based on financial and intellectual property risks, as well as competition from other big biopharma companies, their investigational medicines may not reach peak commercial revenue and could face delays or failures in gaining approval or reimbursement. This could lead to suboptimal commercialization and increased cash burn, which may negatively impact Kodiak's prospects and future growth potential.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of May 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.